We offer target selection/evaluation, drug design and early stage development to research organizations interested in exploring RNA targets either as strategic partnerships or services. The specialization of our platform is to generate highly specific and bioavailable small molecules targeting RNA/protein complexes, as well as systematically identifying safe and effective candidate RNA targets for a given disease indication. These services are ideally suited to researchers with robust phenotypic disease models who wish to evaluate a small, bespoke focused screen of novel molecules. Costing can be tailored to means, from commercially available compounds to ultrahigh specificity novel entities requiring dedicated complex synthesis. 

All RNA is targetable — though not always directly, selectively or safely.  We employ an AI-guided systems biology target selection process, with target interactome analysis to score a candidate RNA drug target for intrinsic safety, targetability, conservation, distribution and efficacy.  This methodology successfully identifies the safety outcomes of existent RNA target clinical trials. Target identification, deconvolution and ranking services are available for any given disease indication. 

Distilling a testable subset of RNA-compatible and synthesizable chemical space using discriminatory machine learning and graph theory. Typically a 1M compound library is selected for virtual screening within 48H.  Acceptable target  engagement is estimated for >⅔  of these compounds. Completely customizable to user needs such as tissue specificity or commercial availability. 

Guided by the latest molecular dynamic parameters alongside novel gridscoring methods and solvent treatment solutions. Outperforms comparable software with 100% bioactive target engagement  validation in vivo.

Original code to design novel molecules. Completely customizable selection criteria, with standard single nucleotide resolution specificity. Predicted bioavailability and specificity regularly improved several fold. Seeking additional strategic partnerships to evaluate designed assets.